Monday - October 20, 2025
AstraZeneca: Tezspire Approved in the U.S. for Chronic Rhinosinusitis With Nasal Polyps
October 18, 2025
WILMINGTON, Delaware, Oct. 18 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation

*

AstraZeneca and Amgen's TEZSPIRE (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult an . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products